Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies
Cet article passe en revue les travaux récents ayant mis en évidence des effets indésirables associés aux immunothérapies anti PD-1/PD-L1, administrées seules ou en combinaison
Immune checkpoint antibodies that augment the PD-1/PD-L1 pathway have demonstrated anti-tumor activity across multiple malignancies, and gained recent regulatory approval as single agent therapy for the treatment of metastatic malignant melanoma and non-small cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. Herein, we review selected published and presented clinical studies investigating single agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anti-cancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies, and their management algorithms.